Ketamine and Psilocybin Update in Treatment-Resistant Depression
Studies from Psych Congress 2022 show the efficacy of ketamine and psilocybin in reducing symptoms of treatment-resistant depression.
Studies from Psych Congress 2022 show the efficacy of ketamine and psilocybin in reducing symptoms of treatment-resistant depression.
Is there a relationship between OSA and cognitive impairment in patients with minor ischemic stroke?
To what extent does second-hand smoke exposure affect respiratory health — and does the effect of this exposure persist over time?
Researchers sought to report on the continuous EEG recordings from the brain of an 87-year-old male who experienced a heart attack after a traumatic subdural hematoma.
How does consumption of processed food by children with atopy and asthma affect the gut microbiota and disease severity?
Is the level of asthma control achieved by preschoolers following their asthma diagnosis an indicator of their likely long-term asthma outcomes?
How prevalent are psychiatric conditions in people with asthma, what are the risk factors for these conditions in this population?
When choosing among alternative treatments for cystic fibrosis exacerbations, what are patients’ and caregivers’ greatest health concerns?